The Market In 5 Minutes: Bitcoin Rally, An IPO Winner, Trump Tweets, And More Mon, 20 Nov 2017 12:15:35 +0000 IN THE NEWS Cryptocurrencies have taken the investment world by storm, as reflected by the strong rally in Bitcoin, the original cryptocurrency. From $968.23 at the end of 2016, Bitcoin has rallied to ...
Novartis to buy French cancer specialist AAA for $3.9 billion Fri, 03 Nov 2017 07:11:28 +0000 Novartis (NOVN.S) has agreed to buy French-based Advanced Accelerator Applications (AAA) (AAAP.O) for $3.9 billion (2.99 billion pounds), giving it a platform in radiopharmaceuticals and access to a new therapy for the kind of cancer that killed Steve Jobs. The deal further strengthens the Swiss drugmaker's oncology business, already boosted by the 2015 acquisition of GlaxoSmithKline's (GSK.L) marketed cancer drugs and August's approval of a ground-breaking gene-modifying leukaemia treatment. The cash offer of $41 per ordinary share and $82 per American depositary share represents a 47 percent premium to AAA's price before media reports on Sept. 27 that Novartis was interested, the two companies said on Monday.
Novartis Buys French Radiopharmaceutical Company Tue, 31 Oct 2017 20:51:08 +0000 Novartis (NVS) plans to acquire France-based Advanced Accelerator Applications. The takeover will add RadioLigand Therapy, Lutathera, in its portfolio with potential to drive growth in the near term.
*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.